Internal Medicine: Neoplasms of the GI Tract and Adnexa

Internal Medicine: Neoplasms of the GI Tract and Adnexa — Expert Guide

How it begins

Neoplasms of the gastrointestinal (GI) tract and its accompanying organs (liver, pancreas, gallbladder and bile ducts) constitute one of the main causes of cancer mortality worldwide. Together, they represent approximately 26% of the global cancer incidence and 35% of oncological mortality, according to GLOBOCAN 2022 data.

What it covers

1. General Epidemiology
2. · Transversal Risk Factors
3. Esophageal Neoplasms
4. · Epidermoid (Squamous) Carcinoma of the Esophagus
5. · Adenocarcinoma of the Esophagus and Barrett's Esophagus
6. · TNM Staging and Treatment
7. Gastric Neoplasms
8. · Gastric Adenocarcinoma
9. · H. pylori and the Correa Sequence
10. · Histological Classification
11. · Gastric MALT Lymphoma
12. · Gastric GIST
13. Small Intestine Neoplasms
14. Colorectal Neoplasms
15. · Colonic Polyps: Classification and Risk
16. · Adenoma → Carcinoma Sequence: Molecular Pathways
17. · Colorectal Adenocarcinoma: Clinical-Pathological Characteristics
18. · Hereditary Colorectal Syndromes
19. Pancreatic Neoplasms
20. · Pancreatic Ductal Adenocarcinoma (PDAC)
21. · Cystic Tumors of the Pancreas
22. · Pancreatic Neuroendocrine Tumors (pNET)
23. Primary and Metastatic Liver Neoplasms
24. · Hepatocellular Carcinoma (HCC / HCC)
25. · Cholangiocarcinoma
26. · Liver Metastases
27. Gallbladder and Biliary Tract Neoplasms
28. · Gallbladder Carcinoma
29. · Perihilar cholangiocarcinoma (Klatskin tumor)
30. Gastrointestinal Neuroendocrine Tumors (GI-NET)
31. · Classification, Histology and Gradation
32. · Functional Syndromes of NETs
33. Gastrointestinal Stromal Tumors (GIST): Global Overview
34. Hereditary Syndromes: Integrated Perspective
35. Diagnosis and Tumor Markers in Digestive Oncology
36. Modern Systemic Oncology in Digestive Tumors
37. · Immunotherapy: Checkpoint Inhibitors in GI Tumors
38. · Antibodies and Antibody-Drug Conjugates (ADC) in GI